ForeSENTIA is a new generation test that identifies genetic alterations involved in cancer. It consists of an extensive portfolio of cancer panels, which provide accurate molecular analysis of the tumor sample taken during biopsy. There are two panel categories, both of which offer indispensable prognostic value, guidance on treatment decisions and increased chance of successful treatment through precision medicine and targeted therapies.

Comprehensive tumor profile panels: Wider coverage of genes implicated in specific cancer types

Therapy-associated tumor profile panels: for selected clinically actionable alterations that are related to targeted therapies.

ADVANTAGES OF ForeSENTIA:

  • Extensive analysis of clinically actionable genetic alterations
  • Detailed molecular classification of the tumor
  • Targeted therapy selection guidance
  • Improved prognostic assessment
  • Informed clinical management
  • Precision technology
  • High sensitivity & specificity

WHAT WILL THE ForeSENTIA REPORT TELL ME?

POSITIVE / NEGATIVE RESULT ON GENETIC ALTERATIONS TESTED

GUIDANCE ON APPROVED TARGETED THERAPIES AND CLINICAL TRIALS

COMPREHENSIVE ANALYSIS ON FINDINGS

COMPREHENSIVE TUMOR PROFILE PANELS

for wide coverage of genes implicated in specific cancer types

Comprehensive tumor profile panels test for an extensive number of clinically actionable genetic alterations that are frequently implicated in solid tumors; therefore giving the healthcare provider a complete molecular profile of the tumor.

  • Detailed molecular classification
  • Deep investigation of tumor heterogeneity
  • Better chances of identifying disease-causing variants

  • BREAST / OVARIAN

    44

  • COLORECTAL

    33

  • LUNG (NSCLC)

    35

  • PROSTATE

    27

  • MELANOMA

    21

  • GLIOMA

    22*

  • PAN-CANCER

    76*

* 1p/19q codeletion is also tested in these panels and reported only in the context of glioma diagnosis.

BREAST/OVARIAN TUMOR PROFILE PANEL

Description

The ForeSENTIA breast/ovarian tumor profile panel tests for numerous genetic alterations that are frequently found in gynecological tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with breast or ovarian cancer can have tumor profile testing with the ForeSENTIA breast/ovarian panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

44

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA beast/ovarian tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Breast/Ovarian Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, ATM, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CHEK2, CTNNB1, DICER1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FOXA1, FOXL2, GATA3, KIT, KRAS, MAP3K1, MRE11A, MTOR, NBN, NRAS, PALB2, PIK3CA, PIK3CB, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, TP53 EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN, TP53 NTRK1, NTRK2, NTRK3

COLORECTAL TUMOR PROFILE PANEL

Description

The ForeSENTIA colorectal tumor profile panel tests for numerous genetic alterations that are frequently found in colorectal tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with colorectal cancer can have tumor profile testing with the ForeSENTIA colorectal cancer panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

33

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA colorectal tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Colorectal Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, APC, ATM, BRAF, BRCA1, BRCA2, CTNNB1, EGFR, ERBB2, FBXW7, GNAS, KRAS, MLH1, MSH2, MSH6, MTOR, NRAS, NTRK1, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAF1, SMAD4, TP53 EGFR, ERBB2, FGFR1, FGFR2, FGFR3, KRAS, MET, TP53 NTRK1, NTRK2, NTRK3

LUNG (NSCLC) TUMOR PROFILE PANEL

Description

The ForeSENTIA lung (NSCLC) tumor profile panel tests for numerous genetic alterations that are frequently found in lung (Non Small Cell Lung Cancers – NSCLC) tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with lung (NSCLC) cancer can have tumor profile testing with the ForeSENTIA lung (NSCLC) panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

35

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA lung (NSCLC) tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Lung (NSCLC) Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, ALK, APC, ARAF, ATM,BRAF, BRCA2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, FBXW7, JAK2, KEAP1, KRAS, MAP2K1, MET, NRAS, PIK3CA, POLE, PTEN, RAF1, SMAD4, STK11, TP53 EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, PIK3CA, PTEN, TP53 ALK, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1

MELANOMA TUMOR PROFILE PANEL

Description

The ForeSENTIA melanoma tumor profile panel tests for numerous genetic alterations that are frequently found in melanomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with melanoma cancer can have tumor profile testing with the ForeSENTIA melanoma panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

21

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA melanoma tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Prostate Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, BRAF, CTNBB1, ERBB2, GNA11, GNAQ, KIT, KRAS, MAP2K1, NF1, NRAS, PIK3CA, POLE, PTEN, TP53 ERBB2, KIT, KRAS, MYC, TP53 ALK, BRAF, NTRK1, NTRK2, NTRK3, RET, ROS1

PROSTATE TUMOR PROFILE PANEL

Description

The ForeSENTIA prostate tumor profile panel tests for numerous genetic alterations that are frequently found in prostate tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with prostate cancer can have tumor profile testing with the ForeSENTIA prostate panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

27

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA prostate tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Prostate Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, APC, AR, ATM, BRAF, BRCA1, BRCA2, CTNNB1, CHEK2, FOXA1, NRAS, PALB2, PIK3CA, PIK3CB, POLE, PTEN, RAD51D, SPOP, TP53 AR, ERBB2, FGFR1, FGFR2, FGFR3, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 TMPRSS2

GLIOMA TUMOR PROFILE PANEL

Description

The ForeSENTIA glioma tumor profile panel tests for numerous genetic alterations that are frequently found in gliomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with glioma cancer can have tumor profile testing with the ForeSENTIA glioma panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

22

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA glioma tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Glioma Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
ATRX, BRAF, CIC, CTNNB1, EGFR, FUBP1, H3F3A, IDH1, IDH2, NF1, POLE, TERT, TP53 1p/19q codeletion, CDKN2A, EGFR, MET, MYC, MYCN, PTEN BRAF, FGFR3, NF1, NTRK1, NTRK2, NTRK3

PAN-CANCER TUMOR PROFILE PANEL

Description

The ForeSENTIA pan-cancer tumor profile panel tests for numerous genetic alterations that are frequently found in several cancers. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with cancer can have tumor profile testing with the ForeSENTIA pan-cancer panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

76

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA pan-cancer tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Pan-Cancer Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, ALK, APC, AR, ARAF, ATM, ATRX, BARD1, BRAF, BRCA1,BRCA2, BRIP1, CHEK2, CIC, CTNNB1,DDR2, DICER1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FBXW7, FOXA1, FOXL2, FUBP1, GATA3,GNA11, GNAQ, GNAS, H3F3A, IDH1, IDH2, JAK2, KEAP1, KIT, KRAS, MAP2K1, MAP3K1, MET, MLH1, MRE11A, MSH2, MSH6, MTOR, NBN, NF1, NRAS, NTRK1, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, SPOP, STK11, TERT, TP53 1p/19q codeletion, AR, CDKN2A, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KIT, KRAS, MET, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 ALK, BRAF, FGFR3, NF1, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2

THERAPY-ASSOCIATED TUMOR PROFILE PANELS

for selected clinically actionable alterations that are related to targeted therapies

Therapy-associated tumor profile panels test for single nucleotide variants (SNVs), insertions and deletions on selected hotspot regions of 1 or 2 genes that are frequently involved in a variety of tumors. Testing of these genes is routinely requested by healthcare professionals due to their implication in tumors. There are several approved* targeted therapies and ongoing clinical trials focusing on these genes.

  • Clinically-actionable, therapy-related alterations
  • Shorter turn-around time
EGFR
Cancers:
Lung
Melanoma
Endometrial
Colorectal
Adenocarcinoma
Breast
KRAS+NRAS
Cancers:
Pancreatic
Colorectal
Lung
Melanoma
Thyroid
Bladder
Endometrial
Thymoma
Testicular
PIK3CA+AKT1
Cancers:
Breast
Endometrial
Colorectal
Cervical
Head and Neck
Bladder
Lung
BRAF
Cancers:
Melanoma
Thyroid
Colorectal
Endometrial
Lung
IDH1+IDH2
Cancers:
Glioma

*FDA (Food and Drug Administration), EMA (European Medicines Agency), PMDA (Pharmaceuticals and Medical Devices Agency, Japan) HCSC (Health Canada Santé Canada)

WHY RECOMMEND ForeSENTIA TO MY PATIENTS?

By thoroughly analyzing the tumor sample for clinically actionable genetic alterations involved in carcinogenesis, ForeSENTIA allows targeted and precise patient treatment.

With ForeSENTIA, you ensure that your patients will have the best therapy option for them - which will improve their chances of survival.

WHAT CAN I DO TO HELP MY PATIENTS AFTER ForeSENTIA?

With the information gained by ForeSENTIA, you will be able to:

  • Prescribe the most suitable therapies for your patients
  • Provide your patients accurate prognosis
  • Identify appropriate clinical trials to enroll your patient

WHAT DOES ForeSENTIA DETECT?

ForeSENTIA detects the 4 main types of genetic alterations known to be implicated in cancer:

Click here to view the table of genes tested by the ForeSENTIA Tumor Profile Panels, and whether the genes examined are tested for Single Nucleotide Variants(SNVs) / Insertions and Deletions, Copy Number Alterations (CNAs), translocations or a combination of variants

WHY CHOOSE ForeSENTIA?

ForeSENTIA thoroughly analyzes the tumor sample for numerous clinically actionable mutated genes involved in cancer development. It is cost effective, time sensitive and clinically valuable.

WHAT ARE THE BENEFITS FOR MY PATIENTS?

  • Ability to select a panel that is most suitable to them
  • Knowledge of eligible clinical trials
  • Invaluable prognostic insight
  • Lower risk of ineffective therapy and adverse effects
  • Higher chances of successful treatment and survival

TECHNOLOGY YOU TRUST

ForeSENTIA uses novel, target capture enrichement technology proven for its precision and accuracy. Analysis of selection regions is performed at an extremely high read-deapth, improving the statistical accuracy of the results. Lastly, genetic and bioinformatics approaches, and multi-engine analysis pipelines have been specifically incorporated to raise the sensitivity and specificity of ForeSENTIA.

TARGETED TECHNOLOGY

ForeSENTIA is based on a novel, target capture enrichment technology that has been validated for its accuracy and precision.

HIGH READ DEPTH

Specifically-designed analytical methods have been incorporated to ensure high read-depth, raising the sensitivity and specificity of the test.

MULTI-ENGINE ANALYSIS

Proprietary bioinformatics pipelines analyze the sequencing data produced from each sample, increasing the sensitivity and specificity of ForeSENTIA

WHAT IS THE POSITION OF PROFESSIONAL BODIES ON PRECISION MEDICINE?

Molecular tumor profiling has become a routine part of cancer patient care. It can help healthcare providers avoid a ‘one-size-fits-all’ approach and instead choose tailored treatments that improve survival chances for cancer patients and spare them potential side effects from drugs that are unlikely to be beneficial. Such advancements in technology and genomics can help physicians in diagnosing, treating and understanding more about human disease, and in selecting treatment that is most likely to help patients.

Source: Food and Drug Administration (FDA), National Comprehensive Cancer Network (NCCN), American Cancer Society, European Society for Medical Oncology (ESMO), Cancer.Net and National Cancer Institute

HOW TO ADMINISTER ForeSENTIA?

  • RECOMMEND THE IDEAL PANEL TO YOUR PATIENT
  • LET THE HISTOPATHOLOGY LAB KNOW THAT ADDITIONAL TESTING WILL BE REQUIRED ON THE TISSUE BIOPSY SAMPLE
  • THE HISTOPATHOLOGY LAB WILL SEND US THE TUMOR SECTIONS
  • THE RESULTS WILL BE SENT TO YOU IN 2-3 WEEKS

Depending on the results, guidance on finding the most appropriate targeted therapies and clinical trials will be provided.

Other Products

NIPD Genetics - Privacy Policy

General Statement

NIPD Genetics is a leading, innovative biotechnology company that designs, develops, and provides a broad spectrum of healthcare services to its customers through its expansive portfolio of molecular and clinical laboratory tests in all disciplines.

At NIPD Genetics we are committed to protecting and respecting our customer’s privacy and personal information. Personal information or personal data means any information that identifies, relates to, describes, is capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular individual, such as name, identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that individual.

NIPD Genetics collects and processes your personal information according to the General Data Protection Regulation (EU) 2016/679 and the Cypriot law providing for the protection of natural persons with regards to the processing of personal data and for the free movement of such data (L. 125(I)/2018). The following principles lie at the heart of our approach to handling personal data:

NIPD Genetics has appointed a Data Protection Officer (DPO) who is responsible for overseeing and ensuring that personal information is collected and processed in line with these principles. The contact details of the Data Protection Officer (DPO) can be found below:

Email address: dpo@nipd.com

Postal address: 31 Neas Engomis street, 2409 Engomi, Nicosia, Cyprus

Telephone number: + 357 22266888

By accessing or using our products or services, or by transmitting information to us by email or other electronic means, you accept our policies, procedures and practices described in this Privacy Policy. If you do not agree with our policies, procedures and practices as described, you can choose not to access or use our products or services or not to transmit personal information to us.

This Privacy Policy applies to NIPD Genetics facilities, its websites www.nipd.com, www.nipdlabs.com, www.nipdlabs.com.cy and their subdomains, that link to this privacy pol icy.

PERSONAL INFORMATION COLLECTION AND PROCESSING

We collect and process several types of personal information from and about users of our websites and of our products and services, including:

Information about children

If you are under 18 years of age, do not register on our website or provide any information about yourself to us. We do not provide our products or services directly to children or proactively collect their personal information. Despite this prohibition, it is possible that we may sometimes be given information about children while handling samples from our customers in our clinical labs, or through use of our products and services by our customers and partners. If we become aware that we have inadvertently collected personal information from children under the age of 18, without parental consent, we will take the necessary steps to delete it as soon as possible in compliance with applicable laws.

LEGAL BASIS FOR PROCESSING OF YOUR PERSONAL INFORMATION

Your personal information is collected by NIPD Genetics for the following purposes:

  1. To provide you with our products and services, respond to your inquiries or fulfill your requests and otherwise manage your relationship with us. The legal basis for processing is to meet the requirements of a contract, to comply with our legal obligations and/or because we have a legitimate interest in responding to requests for information about our products and services.
  2. To communicate with you about content and product offerings, newsletters and event invitations which are relevant to your interests and in line with your preferences. The legal basis for processing is the individual’s explicit consent prior to sending the information and managing individuals preferences.
  3. To process and respond to complaints. The legal basis for processing is to meet a legal obligation.
  4. To monitor and record information relating to the use of our products and services, including our website. The legal basis for processing is our legitimate interest in order to improve our products and services and our website for individuals.

To provide our products and services, NIPD Genetics may collect, receive and process biological samples to isolate and sequence DNA. NIPD Genetics may then store resulting genetic information and use genetic information to provide our products and services. In some cases, NIPD Genetics may provide interpretations of genetic information on behalf of its customers, including healthcare providers. This is only done pursuant to a written contract or a Sample Information Form with a patient’s informed consent and is subject to applicable legal and ethical safeguards.

This sensitive information described above is collected by NIPD Genetics for the following purposes:

  1. To provide support and maintenance services to customers who use our products and services – The legal basis for processing is to meet the requirements of a contract.
  2. To provide genotyping and sequencing services and analysis for our customers, including healthcare providers. The legal basis of this processing is to meet the requirements of a contract or as allowed in the Sample Information Form with a patient’s informed consent.
  3. To conduct genotyping and sequencing services and analysis for quality control, process and product development and improvements, and optimization in our labs to reflect quality improvements and advances in our technology. The legal basis for processing is the patient’s informed consent given through the Sample Information Form.

Transfer of Data

Your information, including personal data, may be transferred to - and maintained on - computers located outside your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

NIPD Genetics will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal information will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the General Data Protection Regulation and will not sell or trade your personal information.

NIPD Genetics may disclose your personal information in the good faith that such action is necessary:

COOKIES AND OTHER TRACKING TECHNOLOGIES

Cookies are files with small amount of data which may include an anonymous unique identifiers. Cookies are sent to your browser when you visit a website and stored on your device. Tracking technologies used on the website are beacons, tags and scripts, to collect and track information and to improve and analyze our websites.

We use cookies and similar tracking technologies to track the activity on our websites and collect certain information. This includes information about the computer or device you are using, such as Internet protocol (IP) address, information about the browser type or version, the pages of our website that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our websites.

Examples of Cookies we may use:

Session Cookies. We use Session Cookies to operate our websites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the websites

Keyword cookies. To understand how visitors discover the websites.

ANALYTICS

We may use third-party Service Providers to monitor and analyze the use of our websites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

SECURITY OF DATA

We are committed to protecting the security of the information we collect, and we take reasonable physical, technical, and administrative safeguards such as data anonymization and encryption to help protect personal information from unauthorized or inappropriate access or use. It is your responsibility to protect the confidentiality of your passwords, and any other access features associated with your access or use of the website or our products and services, as well as to adhere to any applicable Terms of Use or other contract between us and you or your organization.

PERSONAL DATA RETENTION

We may retain collected information even after you remove it from the website, our Services, or our Products, to comply with applicable law, to resolve disputes, to enforce any rights in connection with the website, our Services, or our Products, and to use as provided in this Privacy Policy, the Terms of Use, or an applicable contract between us and you or your organization. How long we retain specific personal information varies depending on the purpose for its use and we may delete or retain your personal information in accordance with applicable law.

SERVICE PROVIDERS

We may employ third party companies and individuals to facilitate, maintain or operate our websites (“Service Providers”), to provide the websites on our behalf, to perform service-related services or to assist us in analyzing how our websites are used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

LINKS TO OTHER SITES

Our websites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

CHANGES TO THIS PRIVACY POLICY

This Privacy Policy may be updated from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our website, prior to the change becoming effective and update the “effective date” at the bottom of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

YOUR LEGAL RIGHTS

NIPD Genetics ensures that it can respond immediately to requests that you make for the exercise of your legal rights in accordance with data protection laws. These rights are as follows:

You also have the right to lodge a complaint at any time to the Office of the Commissioner for Personal Data Protection.

We encourage you to contact us, should you wish to practice any of your legal rights or you have any questions about this Privacy Policy, by sending an email to NIPD Genetics’ Data Protection Officer at dpo@nipd.com.

Effective date: 18/06/2021

Ok got it!